Pharmacogenetics of SSRIs and sexual dysfunction

Pharmaceuticals

Volumn 3, Issue 12, 2010, Pages 3614-3628

  Osis, Liana ^a   Bishop, Jeffrey R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Depressio; Drug metabolism; Glutamate; Polymorphism; Serotonin; Sexual dysfunction; SSRI

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYTOCHROME P450 2D6; FLUOXETINE; GLUTAMIC ACID; PAROXETINE; SERINE PROTEINASE OMI; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AMINO ACID SUBSTITUTION; ANORGASMIA; ANXIETY DISORDER; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ERECTILE DYSFUNCTION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; LIBIDO DISORDER; MAJOR DEPRESSION; PHARMACOGENETICS; PREMATURE EJACULATION; REVIEW; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 78651229223     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3123614     Document Type: Review

References (45)

1. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Koretz, D.; Merikangas, K.R.; Rush, A.J.; Walters, E.E.; Wang, P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289, 3095-3105.
2. Arroll, B.; Macgillivray, S.; Ogston, S.; Reid, I.; Sullivan, F.; Williams, B.; Crombie, I. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann. Fam. Med. 2005, 3, 449-456.
3. Geddes, J.R.; Freemantle, N.; Mason, J.; Eccles, M.P.; Boynton, J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev. 2000, CD001851.
4. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Stewart, J.W.; Nierenberg, A.A.; Thase, M.E.; Ritz, L.; Biggs, M.M.; Warden, D.; Luther, J.F.; Shores-Wilson, K.; Niederehe, G.; Fava, M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006, 354, 1231-1242.
5. Bull, S.A.; Hu, X.H.; Hunkeler, E.M.; Lee, J.Y.; Ming, E.E.; Markson, L.E.; Fireman, B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002, 288, 1403-1409.
6. Sleath, B.; Wurst, K.; Lowery, T. Drug information sources and antidepressant adherence. Community Ment. Health J. 2003, 39, 359-368.
7. Bishop, J.R.; Ellingrod, V.L.; Akroush, M.; Moline, J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum. Psychopharmacol. 2009, 24, 207-215.
8. Clayton, A.H.; Pradko, J.F.; Croft, H.A.; Montano, C.B.; Leadbetter, R.A.; Bolden-Watson, C.; Bass, K.I.; Donahue, R.M.; Jamerson, B.D.; Metz, A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry 2002, 63, 357-366.
9. Montejo, A.L.; Llorca, G.; Izquierdo, J.A.; Rico-Villademoros, F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 2001, 62 (Suppl. 3), 10-21.
10. Ashton, A.K.; Rosen, R.C. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J. Sex Mar. Ther. 1998, 24, 191-192.
11. Montejo-Gonzalez, A.L.; Llorca, G.; Izquierdo, J.A.; Ledesma, A.; Bousono, M.; Calcedo, A.; Carrasco, J.L.; Ciudad, J.; Daniel, E.; De la Gandara, J.; Derecho, J.; Franco, M.; Gomez, M.J.; Macias, J.A.; Martin, T.; Perez, V.; Sanchez, J.M.; Sanchez, S.; Vicens, E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Mar. Ther. 1997, 23, 176-194.
12. Rosen, R.C.; Lane, R.M.; Menza, M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. 1999, 19, 67-85.
13. Stahl, S.M. The psychopharmacology of sex, part 2: effects of drugs and disease on the 3 phases of human sexual response. J. Clin. Psychiatry 2001, 62, 147-148.
14. Perlis, R.H.; Laje, G.; Smoller, J.W.; Fava, M.; Rush, A.J.; McMahon, F.J. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009, 34, 1819-1828.
15. Stahl, S.M. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry 1998, 59 (Suppl. 4), 5-14.
16. Foreman, M.M.; Hall, J.L.; Love, R.L. The role of the 5-HT2 receptor in the regulation of sexual performance of male rats. Life Sci. 1989, 45, 1263-1270.
17. Segraves, R.T. Effects of psychotropic drugs on human erection and ejaculation. Arch. Gen. Psychiatry 1989, 46, 275-284.
18. Keltner, N.L.; McAfee, K.M.; Taylor, C.L. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect. Psychiatr. Care 2002, 38, 111-116.
19. GlaxoSmithKline, Paxil Prescribing Information. 2008.
20. Bradford, L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3, 229-243.
21. Zourkova, A.; Hadasova, E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J. Sex Mar. Ther. 2002, 28, 451-461.
22. Zourkova, A.; Ceskova, E.; Hadasova, E.; Ravcukova, B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J. Sex Mar. Ther. 2007, 33, 343-355.
23. Bishop, J.R.; Moline, J.; Ellingrod, V.L.; Schultz, S.K.; Clayton, A.H. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI- associated sexual side-effects. Neuropsychopharmacology 2006, 31, 2281-2288.
24. Parsons, M.J.; D'Souza, U.M.; Arranz, M.J.; Kerwin, R.W.; Makoff, A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 2004, 56, 406-410.
25. Rosskopf, D.; Busch, S.; Manthey, I.; Siffert, W. G protein beta 3 gene: structure, promoter, and additional polymorphisms. Hypertension 2000, 36, 33-41.
26. Rosskopf, D.; Kielbik, M.; Manthey, I.; Bilmen, G.; Eisenhardt, A.; Siffert, W. Characterization of the splice variant Gbeta3v of the human G-protein Gbeta3 subunit. Biochim. et Biophys. Acta 2003, 1626, 33-42.
27. Clayton, A.H.; McGarvey, E.L.; Clavet, G.J. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol. Bull. 1997, 33, 731-745.
28. Bradley, S.L.; Dodelzon, K.; Sandhu, H.K.; Philibert, R.A. Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 136, 58-61.
29. Hranilovic, D.; Stefulj, J.; Schwab, S.; Borrmann-Hassenbach, M.; Albus, M.; Jernej, B.; Wildenauer, D. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry 2004, 55, 1090-1094.
30. Lesch, K.P.; Gutknecht, L. Pharmacogenetics of the serotonin transporter. Neuro-Psych. Biol. Psych. 2005, 29, 1062-1073.
31. Zou, Y.F.; Wang, Y.; Liu, P.; Feng, X.L.; Wang, B.Y.; Zang, T.H.; Yu, X.; Wei, J.; Liu, Z.C.; Liu, Y.; Tao, M.; Li, H.C.; Li, K.Q.; Hu, J.; Li, M.; Zhang, K.R.; Ye, D.Q.; Xu, X.P. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010, 61, 71-78.
32. Bocchio-Chiavetto, L.; Bagnardi, V.; Zanardini, R.; Molteni, R.; Nielsen, M.G.; Placentino, A.; Giovannini, C.; Rillosi, L.; Ventriglia, M.; Riva, M.A.; Gennarelli, M., Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry 2010, 11, 763-773.
33. McMahon, F.J.; Buervenich, S.; Charney, D.; Lipsky, R.; Rush, A.J.; Wilson, A.F.; Sorant, A.J.; Papanicolaou, G.J.; Laje, G.; Fava, M.; Trivedi, M.H.; Wisniewski, S.R.; Manji, H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78, 804-814.
34. Paddock, S.; Laje, G.; Charney, D.; Rush, A.J.; Wilson, A.F.; Sorant, A.J.; Lipsky, R.; Wisniewski, S.R.; Manji, H.; McMahon, F.J. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry 2007, 164, 1181-1188.
35. Domschke, K.; Lawford, B.; Laje, G.; Berger, K.; Young, R.; Morris, P.; Deckert, J.; Arolt, V.; McMahon, F.J.; Baune, B.T. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol. 2010, 13, 93-101.
36. Laje, G.; Allen, A.S.; Akula, N.; Manji, H.; John Rush, A.; McMahon, F.J. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 2009, 19, 666-674.
37. Janssen, P.K.; Bakker, S.C.; Rethelyi, J.; Zwinderman, A.H.; Touw, D.J.; Olivier, B.; Waldinger, M.D. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J. Sex Med. 2009, 6, 276-284.
38. Safarinejad, M.R. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int. 2009, 105, 73-78.
39. Fiskerstrand, C.E.; Lovejoy, E.A.; Quinn, J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 1999, 458, 171-174.
40. Serretti, A.; Kato, M.; De Ronchi, D.; Kinoshita, T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 2007, 12, 247-257.
41. Murphy, G.M., Jr.; Hollander, S.B.; Rodrigues, H.E.; Kremer, C.; Schatzberg, A.F. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiat. 2004, 61, 1163-1169.
42. Perlis, R.H.; Mischoulon, D.; Smoller, J.W.; Wan, Y.J.; Lamon-Fava, S.; Lin, K.M.; Rosenbaum, J.F.; Fava, M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 2003, 54, 879-883.
43. Aguilera, M.; Arias, B.; Wichers, M.; Barrantes-Vidal, N.; Moya, J.; Villa, H.; van Os, J.; Ibanez, M.I.; Ruiperez, M.A.; Ortet, G.; Fananas, L. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol. Med. 2009, 39, 1425-1432.
44. Pezawas, L.; Meyer-Lindenberg, A.; Goldman, A.L.; Verchinski, B.A.; Chen, G.; Kolachana, B.S.; Egan, M.F.; Mattay, V.S.; Hariri, A.R.; Weinberger, D.R. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol. Psychiatry 2008, 13, 709-716.
45. Terracciano, A.; Tanaka, T.; Sutin, A.R.; Deiana, B.; Balaci, L.; Sanna, S.; Olla, N.; Maschio, A.; Uda, M.; Ferrucci, L.; Schlessinger, D.; Costa, P.T., Jr. BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism. Neuropsychopharmacology 2010, 35, 1083-1089.